Press Releases April 8, 2026 08:00 PM

Nautilus Biotechnology to Announce First Quarter 2026 Financial Results on April 28, 2026

Nautilus Biotechnology to release Q1 2026 financial results with webcast scheduled

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
NAUT

Nautilus Biotechnology, a development stage life sciences firm specializing in proteomics technology, announced it will report its first quarter 2026 financial results on April 28, 2026. The company will host a webcast and conference call to discuss its results, business developments, and outlook.

Nautilus Biotechnology to Announce First Quarter 2026 Financial Results on April 28, 2026
NAUT
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Nautilus will report Q1 2026 financial results before market open on April 28, 2026.
  • The company is pioneering a single-molecule protein analysis platform aimed at advancing proteomics.
  • A webcast and conference call will be held to discuss the financial results and company outlook.

SEATTLE, April 09, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the first quarter 2026 before market open on Tuesday, April 28, 2026.

The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the “Investors” section of the company website at: www.nautilus.bio.

About Nautilus Biotechnology, Inc.
With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio.

Media Contact
[email protected]

Investor Contact
[email protected]


Risks

  • As a development stage company, Nautilus may face uncertainties around commercialization and profitability in the proteomics sector.
  • Financial results may reflect ongoing research and development expenditures without current revenue generation, influencing investor sentiment.
  • Market acceptance and technological success in the competitive life sciences and biotechnology industry remain uncertain.

More from Press Releases

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026 ROMA Green Finance Establishes Dedicated Artificial Intelligence and High-Performance Computing Infrastructure Investment Vertical Jun 12, 2026